Meta-analysis suggests association of L-myc EcoRI polymorphism with cancer prognosis

Monica Spinola, Paola Pedotti, Tommaso A. Dragani, Emanuela Taioli

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The L-myc EcoRI polymorphism is a noncoding variation in the second intron of the L-myc gene, resulting in S and L alleles. Individuals carrying the S allele tend to have poor prognosis and increased risk of several tumor types, although controversial results have been reported. A meta-analysis of 36 studies on L-myc EcoRI. genotyping, including 3563 patients with different types of cancer and 2953 controls, was performed. In lung cancer patients the S/S genotype was significantly associated with lymph node metastasis [odds ratio (OR), 2.8; 95% confidence interval (CI), 1.8-4.3], distant metastasis (OR, 4.7; 95% CI, 2.4-9.2), and stage (OR, 2.3; 95% CI, 1.2-4,4). No association was observed between the S/S genotype and cancer (OR, 1.1; 95% CI, 0.8-1.4). In patients with other cancers, the S/S genotype was significantly associated with tumor recurrence (OR, 2.8; 95% CI, 1.4-6.0), whereas no significant association was seen for the other prognostic parameters. When all types of cancer were examined together, the S/S genotype was associated with lymph node metastasis (OR, 2.3; 95% CI, 1.6-3.3), distant metastasis (OR, 2.9; 95% CI, 1.8-4.6), clinical stage (OR, 1.8; 95% CI, 1.2-2.9), and cancer risk (OR, 1.25; 95% CI, 1.07-1.45). The meta-analysis suggests that the L-myc EcoRI polymorphism is a marker of tumor prognosis in lung cancer and possibly in other types of cancer.

Original languageEnglish
Pages (from-to)4769-4775
Number of pages7
JournalClinical Cancer Research
Volume10
Issue number14
DOIs
Publication statusPublished - Jul 15 2004

Fingerprint

Meta-Analysis
Odds Ratio
Confidence Intervals
Neoplasms
Genotype
Neoplasm Metastasis
Lung Neoplasms
Lymph Nodes
Alleles
myc Genes
Tumor Biomarkers
Introns
Recurrence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Meta-analysis suggests association of L-myc EcoRI polymorphism with cancer prognosis. / Spinola, Monica; Pedotti, Paola; Dragani, Tommaso A.; Taioli, Emanuela.

In: Clinical Cancer Research, Vol. 10, No. 14, 15.07.2004, p. 4769-4775.

Research output: Contribution to journalArticle

Spinola, Monica ; Pedotti, Paola ; Dragani, Tommaso A. ; Taioli, Emanuela. / Meta-analysis suggests association of L-myc EcoRI polymorphism with cancer prognosis. In: Clinical Cancer Research. 2004 ; Vol. 10, No. 14. pp. 4769-4775.
@article{a0b733e513ea46548ab9dbfae20b23b9,
title = "Meta-analysis suggests association of L-myc EcoRI polymorphism with cancer prognosis",
abstract = "The L-myc EcoRI polymorphism is a noncoding variation in the second intron of the L-myc gene, resulting in S and L alleles. Individuals carrying the S allele tend to have poor prognosis and increased risk of several tumor types, although controversial results have been reported. A meta-analysis of 36 studies on L-myc EcoRI. genotyping, including 3563 patients with different types of cancer and 2953 controls, was performed. In lung cancer patients the S/S genotype was significantly associated with lymph node metastasis [odds ratio (OR), 2.8; 95{\%} confidence interval (CI), 1.8-4.3], distant metastasis (OR, 4.7; 95{\%} CI, 2.4-9.2), and stage (OR, 2.3; 95{\%} CI, 1.2-4,4). No association was observed between the S/S genotype and cancer (OR, 1.1; 95{\%} CI, 0.8-1.4). In patients with other cancers, the S/S genotype was significantly associated with tumor recurrence (OR, 2.8; 95{\%} CI, 1.4-6.0), whereas no significant association was seen for the other prognostic parameters. When all types of cancer were examined together, the S/S genotype was associated with lymph node metastasis (OR, 2.3; 95{\%} CI, 1.6-3.3), distant metastasis (OR, 2.9; 95{\%} CI, 1.8-4.6), clinical stage (OR, 1.8; 95{\%} CI, 1.2-2.9), and cancer risk (OR, 1.25; 95{\%} CI, 1.07-1.45). The meta-analysis suggests that the L-myc EcoRI polymorphism is a marker of tumor prognosis in lung cancer and possibly in other types of cancer.",
author = "Monica Spinola and Paola Pedotti and Dragani, {Tommaso A.} and Emanuela Taioli",
year = "2004",
month = "7",
day = "15",
doi = "10.1158/1078-0432.CCR-04-0055",
language = "English",
volume = "10",
pages = "4769--4775",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "14",

}

TY - JOUR

T1 - Meta-analysis suggests association of L-myc EcoRI polymorphism with cancer prognosis

AU - Spinola, Monica

AU - Pedotti, Paola

AU - Dragani, Tommaso A.

AU - Taioli, Emanuela

PY - 2004/7/15

Y1 - 2004/7/15

N2 - The L-myc EcoRI polymorphism is a noncoding variation in the second intron of the L-myc gene, resulting in S and L alleles. Individuals carrying the S allele tend to have poor prognosis and increased risk of several tumor types, although controversial results have been reported. A meta-analysis of 36 studies on L-myc EcoRI. genotyping, including 3563 patients with different types of cancer and 2953 controls, was performed. In lung cancer patients the S/S genotype was significantly associated with lymph node metastasis [odds ratio (OR), 2.8; 95% confidence interval (CI), 1.8-4.3], distant metastasis (OR, 4.7; 95% CI, 2.4-9.2), and stage (OR, 2.3; 95% CI, 1.2-4,4). No association was observed between the S/S genotype and cancer (OR, 1.1; 95% CI, 0.8-1.4). In patients with other cancers, the S/S genotype was significantly associated with tumor recurrence (OR, 2.8; 95% CI, 1.4-6.0), whereas no significant association was seen for the other prognostic parameters. When all types of cancer were examined together, the S/S genotype was associated with lymph node metastasis (OR, 2.3; 95% CI, 1.6-3.3), distant metastasis (OR, 2.9; 95% CI, 1.8-4.6), clinical stage (OR, 1.8; 95% CI, 1.2-2.9), and cancer risk (OR, 1.25; 95% CI, 1.07-1.45). The meta-analysis suggests that the L-myc EcoRI polymorphism is a marker of tumor prognosis in lung cancer and possibly in other types of cancer.

AB - The L-myc EcoRI polymorphism is a noncoding variation in the second intron of the L-myc gene, resulting in S and L alleles. Individuals carrying the S allele tend to have poor prognosis and increased risk of several tumor types, although controversial results have been reported. A meta-analysis of 36 studies on L-myc EcoRI. genotyping, including 3563 patients with different types of cancer and 2953 controls, was performed. In lung cancer patients the S/S genotype was significantly associated with lymph node metastasis [odds ratio (OR), 2.8; 95% confidence interval (CI), 1.8-4.3], distant metastasis (OR, 4.7; 95% CI, 2.4-9.2), and stage (OR, 2.3; 95% CI, 1.2-4,4). No association was observed between the S/S genotype and cancer (OR, 1.1; 95% CI, 0.8-1.4). In patients with other cancers, the S/S genotype was significantly associated with tumor recurrence (OR, 2.8; 95% CI, 1.4-6.0), whereas no significant association was seen for the other prognostic parameters. When all types of cancer were examined together, the S/S genotype was associated with lymph node metastasis (OR, 2.3; 95% CI, 1.6-3.3), distant metastasis (OR, 2.9; 95% CI, 1.8-4.6), clinical stage (OR, 1.8; 95% CI, 1.2-2.9), and cancer risk (OR, 1.25; 95% CI, 1.07-1.45). The meta-analysis suggests that the L-myc EcoRI polymorphism is a marker of tumor prognosis in lung cancer and possibly in other types of cancer.

UR - http://www.scopus.com/inward/record.url?scp=3242730200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242730200&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-04-0055

DO - 10.1158/1078-0432.CCR-04-0055

M3 - Article

C2 - 15269151

AN - SCOPUS:3242730200

VL - 10

SP - 4769

EP - 4775

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 14

ER -